Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
601
datasets available to search
ShareScore release 0.9.0
Dataset results
601 results for “breast cancer resistance”
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT01338831. IPD Sharing: Not stated. Countries: 4. Publications: 1.
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
ClinicalTrials.gov study NCT00046514. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT07066917. IPD Sharing: NO. Countries: 1. Publications: 12.
Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Subs
ClinicalTrials.gov study NCT02671097. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
ClinicalTrials.gov study NCT01298713. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy
ClinicalTrials.gov study NCT01468766. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life
ClinicalTrials.gov study NCT01106820. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
ClinicalTrials.gov study NCT01992952. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Data from: Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy
Metabolites linked to changes in choline kinase-α (CK-α) expression and drug resistance, which contribute to survival and autophagy mechanisms, are attractive targets for breast cancer therapies. We previously reported that autophagy played a causative role in driving tamoxifen (TAM) resistance of breast cancer cells (BCCs) and was also promoted by CK-α knockdown, resulting in the survival of TAM-resistant BCCs. There is no comparative study yet about the metabolites resulting from BCCs with TAM-resistance and CK-α knockdown. Therefore, the aim of this study was to explore the discriminant metabolic biomarkers responsible for TAM resistance as well as CK-α expression, which might be linked with autophagy through a protective role. A total of 33 intracellular metabolites, including a range of amino acids, energy metabolism-related molecules and others from cell extracts of the parental cells (MCF-7), TAM-resistant cells (MCF-7/TAM) and CK-α knockdown cells (MCF-7/shCK-α, MCF-7/TAM/shCK-α) were analyzed by proton nuclear magnetic resonance spectroscopy (1H-NMRS). Principal component analysis (PCA) and partial least square discriminant analysis (PLS-DA) revealed the existence of differences in the intracellular metabolites to separate the 4 groups: MCF-7 cells, MCF-7/TAM cells, MCF-7-shCK-α cells, and MCF-7/TAM/shCK-α cells. The metabolites with VIP>1 contributed most to the differentiation of the cell groups, and they included fumarate, UA (unknown A), lactate, myo-inositol, glycine, phosphocholine, UE (unknown E), glutamine, formate, and AXP (AMP/ADP/ATP). Our results suggest that these altered metabolites would be promising metabolic biomarkers for a targeted therapeutic strategy in BCCs that exhibit TAM-resistance and aberrant CK-α expression, which triggers a survival and drug resistance mechanism.
Figure 4 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 4 The anti-proliferative assay (MTT) was used to examine the EMT-6/P and EMT-6/CPR cell lines' sensitivity to cisplatin at varying doses.
Figure 16 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 16 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum ALT level measured by (IU/L).
Figure 10 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 10 Folds increase in caspase-3 activity and apoptosis induction in concentrations of TQ (10 µM), silymarin (10 µM), and their combination in EMT-6/CPR cell line.
Figure 15 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 15 Changes of tumor sizes in EMT-6/CPR after dissection at day 10 in all groups compared to each other, n = 7.
Figure 14 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 14 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in EMT-6/CPR cell line.
Figure 21 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 21 Showed that there is no significant difference in serum creatinine between the healthy group and other treatment groups except cisplatin group. This graph was obtained by GraphPad Prism.
Figure 9 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 9 Demonstrates concentration of Caspase-3 in ng/ml in each treatment group along with the control group.
Figure 7 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 7 Anti-proliferation activity of several concentrations of TQ with 106.63 µM silymarin against EMT-6/CPR cell lines.
Figure 13 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 13 Shows that the percentage of change in tumor volume in EMT-6/CPR cell line was significant (P-value < 0.05) in all treatment groups except the silymarin group. This graph was obtained using GraphPad prism.
Figure 18 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 18 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum AST level measured by (IU/L).
Figure 12 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 12 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in EMT-6/P cell line.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.